Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can your voice reveal early dementia? new study tests AI speech analysis

NCT ID NCT05380297

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether an automated speech analysis tool called AcceXible can help detect mild cognitive impairment or dementia early. Researchers analyzed speech patterns from 273 adults aged 55 and older, including healthy individuals and those with memory concerns. The goal was to see if changes in how people describe images could signal early cognitive decline, potentially allowing for earlier diagnosis and monitoring in primary care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Speech analysis device
What this could lead to
If successful, this could provide a simple, non-invasive tool for early detection of cognitive decline in routine doctor visits.
What could go wrong
This is a validation study, not a treatment trial. The technology may not be accurate enough for widespread use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

273 people

The number who actually took part.

Started

May 2021

Finished

Apr 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients 55+ years of age with suspected MCI or diagnosis of dementia and obtains a score greater than 20 on the MMSE. * Patients must have agreed to participate in the study and have voluntarily signed the informed consent. * (Healthy) Participants without a diagnosis neurological, or psychiatric disorders. Or taking medication that can affect cognitive abilities. Exclusion Criteria * To have received a diagnosis of a significant psychiatric disorder or other cognitive impairment not due to neurodegeneration. * To have significant vision problems that would affect the ability to perceive visual stimuli. * To have significant hearing problems that would affect the ability to understand verbal cues.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dementia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • País Vasco

    País Vasco, Basque Country, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.